1
WGU D116 ADVANCED PHARMACOLOGY OBJECTIVE
ASSESSMENT ACTUAL EXAM – Questions 200 | Advanced/Hard
Level | APRN Candidates & Graduate Nursing Students | 100%
Pass Guaranteed | Graded A+
1 Which of the following best describes the difference between pharmacokinetics and
pharmacodynamics?
A. Pharmacokinetics is what the drug does to the body; pharmacodynamics is what the body
does to the drug
B. Pharmacokinetics is what the body does to the drug; pharmacodynamics is what the drug
does to the body
C. Pharmacokinetics involves drug efficacy; pharmacodynamics involves drug metabolism
D. There is no clinically significant difference between pharmacokinetics and
pharmacodynamics
☑ Correct Answer: B
☑ Explanation: Pharmacokinetics is the study of what the body does to the drug,
encompassing absorption, distribution, metabolism, and excretion (ADME). Pharmacodynamics
,2
is the study of what the drug does to the body, including its biochemical and physiological
effects and mechanisms of action.
2 The "first-pass effect" refers to:
A. The rapid onset of action following intravenous administration
B. Drug metabolism in the liver before reaching systemic circulation
C. Drug excretion by the kidneys before distribution
D. Drug binding to plasma proteins after absorption
☑ Correct Answer: B
☑ Explanation: The first-pass effect occurs when a drug is metabolized in the liver before
reaching systemic circulation, reducing the bioavailability of orally administered drugs. Drugs
such as nitroglycerin and morphine undergo extensive first-pass metabolism and may require
higher oral doses or alternative routes of administration.
3 Bioavailability is defined as:
A. The speed at which a drug is absorbed from the gastrointestinal tract
,3
B. The fraction of an administered dose that reaches systemic circulation unchanged
C. The total volume of fluid in which a drug is distributed
D. The time required for half of the drug to be eliminated from the body
☑ Correct Answer: B
☑ Explanation: Bioavailability measures the fraction of an administered dose that reaches
the systemic circulation unchanged. Intravenous administration has 100% bioavailability as it
bypasses absorption and first-pass metabolism. Oral bioavailability is reduced by first-pass
metabolism and incomplete absorption.
4 Which route of administration has the highest bioavailability and fastest onset of action?
A. Oral
B. Subcutaneous
C. Intravenous
D. Intramuscular
☑ Correct Answer: C
☑ Explanation: Intravenous administration bypasses absorption barriers and first-pass
, 4
metabolism, delivering 100% of the dose directly into systemic circulation. It provides the most
rapid onset of action and is used in emergencies requiring immediate drug effect.
5 A patient with severe liver cirrhosis is prescribed a highly protein-bound medication (98%
protein bound). What is the primary pharmacokinetic concern in this patient?
A. Decreased renal clearance of the free drug
B. Increased risk of toxicity due to higher levels of free (unbound) drug
C. Accelerated metabolism due to hepatic enzyme induction
D. Prolonged half-life due to increased albumin production
☑ Correct Answer: B
☑ Explanation: Cirrhosis leads to hypoalbuminemia, reducing protein-binding sites and
increasing the fraction of free, pharmacologically active drug. This elevates the risk of toxicity.
Only free drug is pharmacologically active, and decreased protein binding can significantly
increase drug effects.
WGU D116 ADVANCED PHARMACOLOGY OBJECTIVE
ASSESSMENT ACTUAL EXAM – Questions 200 | Advanced/Hard
Level | APRN Candidates & Graduate Nursing Students | 100%
Pass Guaranteed | Graded A+
1 Which of the following best describes the difference between pharmacokinetics and
pharmacodynamics?
A. Pharmacokinetics is what the drug does to the body; pharmacodynamics is what the body
does to the drug
B. Pharmacokinetics is what the body does to the drug; pharmacodynamics is what the drug
does to the body
C. Pharmacokinetics involves drug efficacy; pharmacodynamics involves drug metabolism
D. There is no clinically significant difference between pharmacokinetics and
pharmacodynamics
☑ Correct Answer: B
☑ Explanation: Pharmacokinetics is the study of what the body does to the drug,
encompassing absorption, distribution, metabolism, and excretion (ADME). Pharmacodynamics
,2
is the study of what the drug does to the body, including its biochemical and physiological
effects and mechanisms of action.
2 The "first-pass effect" refers to:
A. The rapid onset of action following intravenous administration
B. Drug metabolism in the liver before reaching systemic circulation
C. Drug excretion by the kidneys before distribution
D. Drug binding to plasma proteins after absorption
☑ Correct Answer: B
☑ Explanation: The first-pass effect occurs when a drug is metabolized in the liver before
reaching systemic circulation, reducing the bioavailability of orally administered drugs. Drugs
such as nitroglycerin and morphine undergo extensive first-pass metabolism and may require
higher oral doses or alternative routes of administration.
3 Bioavailability is defined as:
A. The speed at which a drug is absorbed from the gastrointestinal tract
,3
B. The fraction of an administered dose that reaches systemic circulation unchanged
C. The total volume of fluid in which a drug is distributed
D. The time required for half of the drug to be eliminated from the body
☑ Correct Answer: B
☑ Explanation: Bioavailability measures the fraction of an administered dose that reaches
the systemic circulation unchanged. Intravenous administration has 100% bioavailability as it
bypasses absorption and first-pass metabolism. Oral bioavailability is reduced by first-pass
metabolism and incomplete absorption.
4 Which route of administration has the highest bioavailability and fastest onset of action?
A. Oral
B. Subcutaneous
C. Intravenous
D. Intramuscular
☑ Correct Answer: C
☑ Explanation: Intravenous administration bypasses absorption barriers and first-pass
, 4
metabolism, delivering 100% of the dose directly into systemic circulation. It provides the most
rapid onset of action and is used in emergencies requiring immediate drug effect.
5 A patient with severe liver cirrhosis is prescribed a highly protein-bound medication (98%
protein bound). What is the primary pharmacokinetic concern in this patient?
A. Decreased renal clearance of the free drug
B. Increased risk of toxicity due to higher levels of free (unbound) drug
C. Accelerated metabolism due to hepatic enzyme induction
D. Prolonged half-life due to increased albumin production
☑ Correct Answer: B
☑ Explanation: Cirrhosis leads to hypoalbuminemia, reducing protein-binding sites and
increasing the fraction of free, pharmacologically active drug. This elevates the risk of toxicity.
Only free drug is pharmacologically active, and decreased protein binding can significantly
increase drug effects.
